Literature DB >> 24903345

Medical therapy for uveal effusion syndrome.

B Andrijević Derk1, G Benčić1, V Corluka2, M Zorić Geber1, Z Vatavuk1.   

Abstract

PURPOSE: To report a case series of three patients with bilateral uveal effusion syndrome (UES), treated conservatively with oral carbonic anhydrase inhibitors and topical prostaglandin analogues (PAs).
METHODS: Three patients with bilateral UES were treated with the same initial therapy. Topical PA latanoprost 0.005% and acetazolamide 250 mg were administered in order to reduce intraocular pressure, improve uveoscleral outflow, and facilitate resolution of uveal effusion.
RESULTS: The chorioretinal detachment resolved within 3 months in two reported patients while the third one underwent surgery on his left eye. After clinical improvement, further oral therapy with acetazolamide was stopped, while topical prostaglandins were continued for at least the next 3 months. All patients were free from recurrence during the follow-up period.
CONCLUSION: Although the usually recommended UES therapy is partial or full-thickness sclerectomy, our case series showed apparent resolution of chorioretinal detachment in two patients on medical therapy alone. Conservative therapy may be the first step before the standard recommended surgical approach, but further studies are needed to verify the effectiveness of reported therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903345      PMCID: PMC4135252          DOI: 10.1038/eye.2014.126

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  12 in total

1.  The indocyanine green findings in idiopathic uveal effusion syndrome.

Authors:  Atul Kumar; Sachin Kedar; Rajinder P Singh
Journal:  Indian J Ophthalmol       Date:  2002-09       Impact factor: 1.848

2.  UVEAL EFFUSION. 1. CLINICAL PICTURE.

Authors:  C L SCHEPENS; R J BROCKHURST
Journal:  Arch Ophthalmol       Date:  1963-08

3.  Scleral hydraulic conductivity and macromolecular diffusion in patients with uveal effusion syndrome.

Authors:  Timothy L Jackson; Ali Hussain; Ana M S Morley; Paul M Sullivan; Andrea Hodgetts; Austen El-Osta; Jost Hillenkamp; Stephen J Charles; Richard Sheard; Tom H Williamson; Anupma Kumar; D Alistair H Laidlaw; W Hong Woon; Mark J Costen; Andrew J Luff; John Marshall
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-14       Impact factor: 4.799

4.  Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB.

Authors:  B Moldow; B Sander; M Larsen; H Lund-Andersen
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-07       Impact factor: 4.799

5.  Enhancement of scleral macromolecular permeability with prostaglandins.

Authors:  R N Weinreb
Journal:  Trans Am Ophthalmol Soc       Date:  2001

6.  Nanophthalmic uveal effusion.

Authors:  K M Allen; S M Meyers; H Zegarra
Journal:  Retina       Date:  1988       Impact factor: 4.256

7.  Nanophthalmos with uveal effusion. A new clinical entity.

Authors:  R J Brockhurst
Journal:  Arch Ophthalmol       Date:  1975-12

8.  Uveal effusion syndrome. A new hypothesis concerning pathogenesis and technique of surgical treatment.

Authors:  J D Gass
Journal:  Retina       Date:  1983       Impact factor: 4.256

9.  Scleral window surgery and topical mitomycin C for nanophthalmic uveal effusion complicated by renal failure: case report.

Authors:  Yumi Suzuki; Sachiko Nishina; Noriyuki Azuma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.535

10.  Scleral thickness in human eyes.

Authors:  Sujiv Vurgese; Songhomitra Panda-Jonas; Jost B Jonas
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

View more
  4 in total

1.  Four quadrant sclerotomies for uveal effusion syndrome.

Authors:  B Z Wang; B Clark; P McKelvie; B J Matthews; R G Buttery; A Chandra
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

2.  Reply to: 'Four quadrant sclerotomies for uveal effusion syndrome'.

Authors:  B Andrijević Derk; G Benčić; V Corluka; M Zorić Geber; Z Vatavuk
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

3.  Unusual rapid resolution of postsclerectomy exudative retinal detachment with topical NSAIDs therapy in a case of nanophthalmos.

Authors:  Boding Tong; Chao Wang; Xin Qi
Journal:  J Int Med Res       Date:  2019-05-13       Impact factor: 1.671

4.  Treatment of Nanophthalmos-Related Uveal Effusion with Two- vs. Four-Quadrant Partial-Thickness Sclerectomy and Sclerotomy Surgery

Authors:  Şengül Özdek; Duygu Yalınbaş Yeter; Mehmet Cüneyt Özmen; Murat Hasanreisoğlu
Journal:  Turk J Ophthalmol       Date:  2022-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.